In the trial-product estimand analysis (accounting for treatment adherence), reductions reached 22.7% and 2.3%, respectively, corresponding to an absolute weight loss of -21.6 kg with combination therapy
Type 2 diabetes (Phase 2, randomized controlled trial): a separate randomized Phase 2 trial published in The Lancet documented strong glycemic control in type 2 diabetes
Its also important to talk to your healthcare team about how youre feeling
Enhances Mood and Mental Health: B12 plays a role in synthesizing neurotransmitters, which can improve mood and reduce symptoms of depression and anxiety
Patients should be aware that: No licensed combination product exists in the UK Any combination use would be considered experimental and is not supported by current evidence Clinical decisions must be guided by a qualified healthcare professional with access to current trial data Clinical Evidence and Trial Data Available to UK Patients Retatrutide Phase 2 data showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, but no published trial data exist for the specific cagrilintideretatrutide combination
Modified melasma area and severity index (MASI) score was calculated before and after therapy
